[CAS NO. 18323-44-9] Clindamycin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [18323-44-9]

Catalog

HY-B1455

Brand

MCE

CAS

18323-44-9

DESCRIPTION [18323-44-9]

Overview

MDL	-
Molecular Weight	424.98
Molecular Formula	C18H33ClN2O5S
SMILES	CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

Summary

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic . Clindamycin can inhibit bacterial protein synthesis , possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria ^[1] ^[2] .

IC50 & Target

Plasmodium

In Vitro

Clindamycin (25 μg/mL, 1-18 h) inhibits ceftazidime ( HY-B0593 )-induced endotoxin release pretreatment in E. coli O55:B5 ^[3] .
Clindamycin (50-100 μg/mL, 0-12 min) enhances antibody- and complement-dependent phagocytosis in Staphylococcus aureus ^[4] .
Clindamycin (0-500 μg/mL, 24-72 h) inhibits the cell proliferation in osteoblast cell culture model, stimulates the cell metabolism of osteoblast at the contratibution of 10 μg/mL ^[5] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[3]

Cell Line:	THP-1 cells with stimulated E. coli O55:B5
Concentration:	3.13-50 μg/mL
Incubation Time:	1-18 h
Result:	Reduced TNF-α concentrations after pretreatment for 4 or 18 h at 25 and 50 μg/mL.

Cell Viability Assay ^[5]

Cell Line:	Osteoblast cell culture model
Concentration:	0-500 μg/mL
Incubation Time:	24-72 h
Result:	Increased alkaline phosphatase (ALP)-activity at 10 μg/mL at 24 and 48 h. Increased LDH values at 500 μg/mL at 24 and 48 h, indicating cytotoxicity. Increased calcification at 10 and 25 μg/mL,decreased or no calcification was found at 50 μg/ml.

In Vivo

Clindamycin (50-300 mg/kg; i.v., p.o.) dosage doesn’t affect pharmacokinetic parameters in rats ^[6] .
Clindamycin (160-600 mg/kg; i.v.) improves survival in a dose-dependent manner in endotoxic shock mouse model ^[7] .
Clindamycin (17-50 mg/kg, i.v.) has good penetration into rat muscle tissue that can be applied to inhibit the main bacteria causing odontogenic infections ^[8] .

1.19
Pharmacokinetic Analysis in Rat Model ^[8]

Route	Dose (mg/kg)	t _1/2 (h)	C _max (mg/mL)	T _max (h)a	AUC _0-inf (h.mg/L)	∱T
i.v.	51(Plasma)	2.51 (2.37–2.83)	35.21 (25.04–42.65)	0.08 ± 0.00	44.78 (28.82–65.65)	/
i.v.	51(Tissue)	2.82 (2.57–3.05)	14.20 (10.63–14.89)	0.25 ± 0.00	16.54 (13.83–18.35)	1.10
i.v.	17(Tissue)	3.25 (3.13–3.44)	4.82 (3.35–6.66	0.25 ± 0.00	/	/

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Endotoxic shock mouse model ^[7]
Dosage:	160-600 mg/kg
Administration:	Intravenous injection (i.v.)
Result:	Decreased survival rates to 92 and 36% treated with 520- and 600-mg/kg doses. Lowered the peak concentrations of tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in serum. Increased the the peak concentrations of IL-6 in the sera.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03412071	University of Toronto\|UVRI-IAVI HIV Vaccine Program\|Entebbe General Hospital	Foreskin HIV Susceptibility	December 7, 2017	Not Applicable
NCT00689117	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris\|Acne	April 2008	Phase 3
NCT02515305	Padagis LLC	Acne	July 2015	Phase 3
NCT01464138	Jomaa Pharma GmbH\|Fundacio Clinic Barcelona\|Hospital Clinic of Barcelona	Malaria	September 2010	Phase 2
NCT00352612	Aaron Chen\|Thrasher Research Fund\|Johns Hopkins University	Staphylococcal Infection\|Abscess\|Staphylococcal Skin Infection\|Folliculitis	September 2006	Phase 4
NCT02595034	Taro Pharmaceuticals USA	Acne Vulgaris	January 2015	Phase 1
NCT03261830	Sumit Gupta\|University of Missouri-Columbia	Supracondylar Humerus Fracture\|Post Operative Wound Infection	August 18, 2017	Phase 4
NCT05137119	University of Melbourne\|Berry Consultants\|McGill University Health Centre+Research Institute of the McGill University Health Centre\|Menzies School of Health Research\|Middlemore Clinical Trials\|Queensland University of Technology\|Sunnybrook Health Sciences Centre\|Tan Tock Seng Hospital\|Telethon Kids Institute\|The Peter Doherty Institute for Infection and Immunity\|The University of Queensland	Staphylococcus Aureus Bacteremia	February 16, 2022	Phase 4
NCT05762484	Erasmus Medical Center	Hidradenitis Suppurativa, Acne Inversa	April 2023	Not Applicable
NCT00664248	Dow Pharmaceutical Sciences	Acne Vulgaris	October 2006	Phase 3
NCT04516148	Medstar Health Research Institute	Burn\|Surgery\|Infection Wound	May 29, 2018	Phase 4
NCT02579161	Northwell Health	Kidney Stones	September 2014	Phase 3
NCT01769235	Taro Pharmaceuticals USA	Acne Vulgaris	November 2012	Phase 1
NCT05398679	Fundacion Clinic per a la Recerca Biomédica	Endocarditis Infective	June 1, 2022	Phase 4
NCT00713609	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	June 2008	Phase 2
NCT00776919	Stiefel, a GSK Company\|Rho, Inc.\|Quintiles, Inc.\|GlaxoSmithKline	Acne Vulgaris	October 2008	Phase 3
NCT03779360	Centre for Human Drug Research, Netherlands\|Maruho Co., Ltd.	Inflammation; Skin	October 12, 2018	Not Applicable
NCT01619410	University of Chicago\|Pfizer	Skin Diseases, Bacterial\|Abscess	January 2012	Not Applicable
NCT01500837	Assistance Publique - Hôpitaux de Paris	Osteoarticular Infection	October 2010	Not Applicable
NCT02141217	GlaxoSmithKline	Focal Infection, Dental	March 21, 2013	Phase 4
NCT01744730	Phillip Brian Smith\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|The Emmes Company, LLC\|Duke University	Bacterial Infections\|Obesity	June 2013	Phase 1
NCT00663286	Dow Pharmaceutical Sciences	Acne Vulgaris	October 2006	Phase 3
NCT01769664	Taro Pharmaceuticals USA	Acne Vulgaris	September 2012	Phase 1
NCT05899140	Frieder Schaumburg\|Westfälische Wilhelms-Universität Münster	Skin Infection\|Staphylococcal Infections\|Staphylococcus Aureus Infection	August 1, 2023	Phase 4
NCT04067531	Skaraborg Hospital	Infection, Bacterial	August 1, 2020	Phase 3
NCT02578043	Taro Pharmaceuticals USA	Acne Vulgaris	April 2015	Phase 1
NCT00642980	University Hospital, Lille\|Pfizer	Pregnancy	April 2006	Phase 4
NCT01915732	GlaxoSmithKline	Acne Vulgaris	April 2013	Phase 3
NCT03522441	Akorn, Inc.	Acne Vulgaris	April 27, 2018	Phase 3
NCT01127880	St. Luke´s Hospital, Pennsylvania	Hemopneumothorax\|Pneumothorax	July 2005	Phase 2\|Phase 3
NCT00616330	Lumara Health, Inc.	Vulvovaginitis\|Vaginitis	January 2008	Phase 3
NCT00729937	National Institute of Allergy and Infectious Diseases (NIAID)	Staphylococcal Infection	April 2009	Phase 2\|Phase 3
NCT01111994	Callender Center for Clinical Research\|Society Hill Dermatology	Acne	November 2009	Phase 4
NCT00377000	Sanofi	Acne Vulgaris	November 2005	Phase 4
NCT01293643	Merck Sharp & Dohme LLC	Vaginosis, Bacterial\|Candidiasis, Vulvovaginal	May 2010	Phase 3
NCT03883269	Centre for Human Drug Research, Netherlands\|Maruho Co., Ltd.	Acne Vulgaris	March 20, 2018	Phase 4
NCT01800825	Christiana Care Health Services\|Jawaharlal Nehru Medical College\|Thrasher Research Fund	Pregnancy\|Prematurity\|Preterm Birth\|Bacterial Vaginosis	July 2013	Phase 4
NCT02809131	Vanderbilt University Medical Center\|Thomas Jefferson University\|The Cooper Health System\|Valley Health System\|Medtronic	Sick Sinus Syndrome\|Complete Heart Block\|Syncope\|Chronic Systolic Heart Failure	April 1, 2016	Phase 3
NCT01722708	HaEmek Medical Center, Israel	Abnormal Vaginal Flora\|Clindamycin Vs Metronidazole\|High Risk Pregnancies for Preterm Labor	April 2012	Not Applicable
NCT00361322	Hadassah Medical Organization	Acne Vulgaris	April 2005	Phase 1\|Phase 2
NCT03945357	Prisma Health-Upstate\|Washington University School of Medicine\|The Cleveland Clinic\|Penn State University\|Oregon Health and Science University\|Ohio State University\|New Hanover Regional Medical Center\|University of Pennsylvania	Ventral Hernia Repair	May 15, 2019	Phase 3
NCT00823901	Massachusetts General Hospital\|Medicis Pharmaceutical Corporation	Rosacea	February 2009	Phase 2\|Phase 3
NCT05177198	Cairo University	Periodontal Intrabony Defects	March 2022	Not Applicable
NCT03033472	Cairo University	Symptomatic Periapical Periodontitis		Phase 2\|Phase 3
NCT01823523	Atlantic Center for Oral and Maxillofacial Surgery	Dentofacial Deformity	June 2013	Not Applicable
NCT00836004	Teva Pharmaceuticals USA	Healthy	November 2003	Phase 1
NCT03080740	Guangzhou Yipinhong Pharmaceutical CO.,LTD	Bacterial Vaginosis	July 2016	Phase 4
NCT00814905	United States Naval Medical Center, Portsmouth	Chorioamnionitis	June 2009	Not Applicable
NCT03717506	Gage Development Company, LLC	Acne Vulgaris	October 10, 2018	Phase 3
NCT01052246	Laserklinik Karlsruhe	Acne Vulgaris	October 2008	Not Applicable
NCT01796665	Padagis LLC	Acne	February 2012	Phase 3
NCT00000717	National Institute of Allergy and Infectious Diseases (NIAID)	Pneumonia, Pneumocystis Carinii\|HIV Infections		Not Applicable
NCT00219570	Pfizer\|Parexel\|SACT INTERNATIONAL Co., LTD.\|Acronet\|Bellsystem24 , Inc.\|Mitsubishi Kagaku Bio-Clinical Laboratories, inc\|SATO Pharmaceutical Co., Ltd.	Acne Vulgaris	January 2005	Phase 4
NCT01063270	Henry Ford Health System	Hidradenitis Suppurativa	February 2010	Not Applicable
NCT03779295	West Virginia University	Perioral Dermatitis	November 1, 2018	Not Applicable
NCT04321070	Taro Pharmaceuticals USA	Acne Vulgaris	September 9, 2019	Phase 1
NCT00694928	Lumara Health, Inc.	Vaginal Infection	May 2008	Phase 3
NCT00887484	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	February 2009	Phase 4
NCT04134273	Taro Pharmaceuticals USA	Acne Vulgaris	March 20, 2019	Phase 1
NCT00473083	British Columbia Cancer Agency\|Hoffmann-La Roche	Rash	January 2009	Phase 2
NCT00398658	Shahid Beheshti University of Medical Sciences	Endophthalmitis\|Prophylaxy of Post Traumatic Endophthalmitis\|Bacterial Endophthalmitis	March 2002	Phase 4
NCT02314806	Hospital General Universitario Elche	Breast Cancer	January 2013	Phase 3
NCT04469075	Memorial Sloan Kettering Cancer Center	Glioblastoma\|Recurrent Glioblastoma\|Skin Toxicity	July 9, 2020	Phase 2
NCT01047189	Wake Forest University\|Medicis Pharmaceutical Corporation\|Wake Forest University Health Sciences	Acne Vulgaris	March 2009	Phase 4
NCT02721173	All India Institute of Medical Sciences, Bhubaneswar	Acne Vulgaris	April 2016	Phase 4
NCT04502095	Roswell Park Cancer Institute	Bladder Carcinoma\|Refractory Bladder Carcinoma\|Urinary Tract Infection	September 2, 2020	Phase 4
NCT04104178	Hvidovre University Hospital	MRSA\|MRSA Colonization	May 20, 2020	Phase 3
NCT03560232	Mercy Health Ohio	Open Fracture\|Post-Op Wound Infection	July 9, 2018	Phase 4
NCT01945450	Hadassah Medical Organization	Endometritis	January 2014	Not Applicable
NCT01361269	Zentopharm GmbH\|Albert Schweitzer Hospital\|Centro de Investigacao em Saude de Manhica	Malaria	June 2011	Phase 2
NCT00964366	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	July 2009	Phase 4
NCT00911573	Wyeth is now a wholly owned subsidiary of Pfizer	Skin Diseases\|Infection	August 2011	Phase 3
NCT04980170	Jordan University Hospital	Antibiotics Causing Adverse Effects in Therapeutic Use	November 1, 2021	Early Phase 1
NCT01374581	Universiteit Antwerpen\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|Fund for Scientific Research, Flanders, Belgium\|Institute of Tropical Medicine, Belgium\|University of Kinshasa\|Centre Muraz\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Makerere University	Malaria	May 2012	Phase 3
NCT01015638	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	August 2009	Phase 4
NCT00926367	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	May 2009	Phase 4
NCT01132443	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	May 6, 2010	Phase 1
NCT00000640	National Institute of Allergy and Infectious Diseases (NIAID)\|Jacobus Pharmaceutical\|Glaxo Wellcome	Pneumonia, Pneumocystis Carinii\|HIV Infections		Phase 3
NCT01715610	Lawson Health Research Institute	Peritonsillar Abscess	May 24, 2012	Not Applicable
NCT01792804	Heinrich-Heine University, Duesseldorf\|German Research Foundation	Staphylococcus Aureus Infection	December 2013	Phase 3
NCT03478163	Cedars-Sinai Medical Center	Obstetric Complication\|Postpartum Hemorrhage\|Postpartum Endometritis	March 8, 2018	Phase 4
NCT01422785	Zeichner, Joshua, M.D.	Acne Vulgaris	July 2011	Phase 4
NCT02465632	Glenmark Pharmaceuticals Ltd. India	Acne Vulgaris	April 2015	Phase 3
NCT02058628	GlaxoSmithKline	Acne Vulgaris	February 21, 2014	Phase 4
NCT02782078	Assistance Publique - Hôpitaux de Paris	Staphylococcal Infections	March 6, 2017	Not Applicable
NCT00836056	Teva Pharmaceuticals USA	Healthy	November 2003	Phase 1
NCT02005666	Zydus Lifesciences Limited	Acne Vulgaris	November 2013	Phase 3
NCT01138514	Padagis LLC	Acne Vulgaris	October 2009	Phase 3
NCT01400867	Forest Laboratories\|AstraZeneca	Infections, Pediatrics	December 2011	Phase 2\|Phase 3
NCT01498744	Ann & Robert H Lurie Children´s Hospital of Chicago	Abscess Soft Tissue\|Methicillin-resistant Staphylococcus Aureus (MRSA) Infection\|Skin Abscess	February 2010	Not Applicable
NCT02210689	Actavis Inc.\|Watson Laboratories, Inc.	BACTERIAL VAGINOSIS\|Signs and Symptoms to be Evaluated and Recorded Include\|Vaginal Discharge Color, Odor, and Consistency\|Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe\|Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe	January 2014	Phase 3
NCT03476941	Paolo Goffredo\|University of Iowa	Abdominal Abscess	April 1, 2019	Phase 2
NCT01788384	Watson Laboratories, Inc.	Acne Vulgaris	July 2012	Phase 3
NCT02585141	University of Southern Denmark\|Odense University Hospital	Anal Fistulas	October 2015	Not Applicable
NCT04194216	Stanford University\|Washington University School of Medicine\|Vanderbilt University School of Medicine\|University of Washington\|Duke University\|Harvard University\|University of Kansas Medical Center\|University of Cincinnati\|Loma Linda University	Nasal Obstruction\|Nasal Surgical Procedures	May 20, 2020	Phase 3
NCT05846399	University of Missouri-Columbia	Cat Bite\|Hand Injuries\|Arm Injury\|Infection, Bacterial\|Anti-bacterial Agents	September 1, 2023	Phase 4
NCT02018094	Hull University Teaching Hospitals NHS Trust\|University of Hull	Wound Infection\|Amputation Wound	October 8, 2013	Phase 4
NCT03173053	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|University College, London	Staphylococcus Aureus\|Motility Disorder	February 8, 2018	Not Applicable
NCT01757236	University Hospital, Tours\|Pfizer\|International Clinical Trials Association	Hip Prosthetic Joint Infection	October 2012	Phase 2
NCT00000674	National Institute of Allergy and Infectious Diseases (NIAID)\|Upjohn\|Glaxo Wellcome	Toxoplasmosis, Cerebral\|HIV Infections		Not Applicable
NCT02475876	Michael Cohen-Wolkowiez\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Duke University	Bacterial Infections	November 2015	Phase 1
NCT01016977	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	October 2009	Phase 4
NCT01874860	University of Louisville\|James Graham Brown Cancer Center	Colorectal Cancer\|Head and Neck Cancer	August 2013	Phase 2
NCT05582434	Wake Forest University Health Sciences\|Bausch Health Americas, Inc.	Acne	August 2023	Early Phase 1
NCT00730028	National Institute of Allergy and Infectious Diseases (NIAID)	Staphylococcal Infection	April 2009	Phase 2
NCT04349410	The Camelot Foundation	CoVid 19 Positive	April 11, 2020	Phase 2\|Phase 3
NCT05867654	University of Louisville\|Osteo Science Foundation	Osteomyelitis of Jaw	May 1, 2023
NCT00837213	Stiefel, a GSK Company\|GlaxoSmithKline	Acne	August 2007	Phase 4
NCT05223400	Alexandria University	Infection, Bacterial	March 1, 2022
NCT04723940	Rothman Institute Orthopaedics	Joint Infection	January 25, 2021	Phase 3
NCT03374176	Centro Universitario de Tonalá	Periodontitis\|Periodontal Pocket\|Diabetes Mellitus	March 2014	Phase 3
NCT01155154	State University of New York - Downstate Medical Center\|Staten Island University Hospital\|Kings County Hospital Center	Simple Hand Lacerations	February 2010	Not Applicable
NCT02730962	University of Minnesota	Pre-Diabetes	June 2016	Phase 2
NCT05926869	Jinnah Postgraduate Medical Centre	Acne Vulgaris	August 1, 2022	Phase 2
NCT03615768	Lee´s Pharmaceutical Limited\|Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Acne Vulgaris	August 14, 2018	Phase 3
NCT03234517	Zagazig University	Bacterial Vaginosis Treatment	August 1, 2016	Phase 2
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT00503542	Agency for Healthcare Research and Quality (AHRQ)	Vaginitis	February 2007	Early Phase 1
NCT02593383	Lee´s Pharmaceutical Limited	Acne	March 1, 2015	Phase 1\|Phase 2
NCT00214643	Albert Schweitzer Hospital	Malaria	June 2005	Phase 3
NCT01876628	University Hospitals Bristol and Weston NHS Foundation Trust\|University of Bristol\|Public Health England	Cellulitis	October 2013	Phase 4
NCT02309346	Hospital de Clinicas de Porto Alegre	Septic Abortion	December 31, 2014	Phase 4
NCT00889356	Zodiac Produtos Farmaceuticos S.A.	Candidiasis\|Bacterial Vaginosis	September 2009	Phase 3
NCT02860845	Laboratorios Ordesa\|Clever Instruments S.L.	Candidiasis\|Vaginosis, Bacterial	July 12, 2016	Phase 4
NCT03257202	University of Southern California	Surgical Site Infection	September 11, 2017	Phase 2
NCT01994993	Michael Cohen-Wolkowiez\|The Emmes Company, LLC\|Duke University	Complicated Intra Abdominal Infections	December 2013	Phase 2\|Phase 3
NCT00964223	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	July 2009	Phase 4
NCT01125410	Medinova AG	Bacterial Vaginosis	January 2007	Phase 3
NCT00002064	Palo Alto Medical Foundation\|NIH AIDS Clinical Trials Information Service	Toxoplasmosis, Cerebral\|HIV Infections		Not Applicable
NCT05166746	Peter Humaidan\|Regionshospitalet Viborg, Skive	Bacterial Vaginoses\|Infertility, Female	December 7, 2017	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 294.13 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3531 mL	11.7653 mL	23.5305 mL
5 mM	0.4706 mL	2.3531 mL	4.7061 mL
10 mM	0.2353 mL	1.1765 mL	2.3531 mL

* Please refer to the solubility information to select the appropriate solvent.